Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 6-Week, Double-Blind, Placebo- Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression

Next Previous
Search
Trial Profile

A Randomized, 6-Week, Double-Blind, Placebo- Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lurasidone (Primary) ; Lithium; Valproate
  • Indications Bipolar I disorders
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms PREVAIL-1
  • Sponsors Dainippon Sumitomo Pharma; Sunovion Pharmaceuticals

    • Most Recent Events

    • 07 Jun 2023 Results of post hoc, pooled analysis NCT00868699 and NCT00868452, assessing the effects of lurasidone on anxiety symptoms and sleep disruption, and their moderating and mediating roles on treatment response in bipolar depression, analysis published in the Journal of Clinical Psychiatry
    • 05 Oct 2021 Results of post-hoc pooled analysis relationships between symptoms of anxiety and depression while controlling for the moderating effects of the specific subthreshold manic symptom of sleep disturbance (decreased need for sleep), and their implications for treatment response to lurasidone in patients with bipolar depression in two studies (Prevail-1 & Prevail-2) presented at the 34th Annual Congress of the European College of Neuropsychopharmacology.
    • 03 May 2021 Acccording to the Sunovion Pharmaceuticals media release, results of post-hoc pooled analysis from two placebo-controlled studies on lurasidone as monotherapy and as adjunctive therapy with lithium or valproate in adult patients with bipolar depression presented at the American Psychiatric Association Annual Meeting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top